Medtronic announced today (1/14) the launch of its clinical trial enrollment of the innovative Adaptive DBS Algorithm for Personalized Therapy in Parkinson’s Disease (ADAPT-PD). The novel trial, which will take place across 12 research study sites in the US, Europe and Canada, will test the efficacy and safety of adaptive deep brain stimulation (aDBS) in patients diagnosed with Parkinson’s Disease. Depending on the patient’s clinical state, the innovative technology automatically changes the brain stimulation to help manage the symptoms of Parkinson’s disease on a case-by-case basis.

Read more here.

More on: